DAPK1: a Novel Pathology and Treatment Target for Alzheimer’s Disease

被引：0
作者：
Ling-zhi Xu
Bing-qiu Li
Jian-ping Jia
机构：
[1] Capital Medical University,Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital
[2] Beijing Key Laboratory of Geriatric Cognitive Disorders,Clinical Center for Neurodegenerative Disease and Memory Impairment
[3] Capital Medical University,Center of Alzheimer’s Disease
[4] Beijing Institute for Brain Disorders,Key Laboratory of Neurodegenerative Diseases
[5] Ministry of Education,undefined
[6] National Clinical Research Center for Geriatric Disorders,undefined
来源：
Molecular Neurobiology | 2019年 / 56卷
关键词：
Death-associated protein kinase 1; Alzheimer’s disease; Variants; Neuropathology; Therapeutics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Alzheimer’s disease (AD) is the most common neurodegenerative disease and seriously damages the health of elderly population. Clinical drug research targeting at classic pathology hallmarks, such as amyloid-β (Aβ) and tau protein, failed to achieve effective cognitive improvement, suggesting that the pathogenesis of AD is much complicated, and there are still other unknown and undetermined important factors. Death-associated protein kinase 1 (DAPK1) is a calcium/calmodulin-dependent serine/threonine kinase that plays an important role in various neuronal injury models. Mounting evidence has demonstrated that DAPK1 variants are associated with AD risk. The activation of DAPK1 is also involved in AD-related neurodegeneration in the brain. Exploring the roles of DAPK1 in AD might help us understand the pathogenic mechanisms and find a novel promising therapeutic target in AD. Therefore, in this review, we comprehensively summary the main progress of DAPK1 in the AD studies from genetic risk, neuropathological process, and clinical potential implications.
引用
收藏
页码：2838 / 2844
页数：6
相关论文
共 513 条
[1]  
Scheltens P(2016)Alzheimer’s disease Lancet (London, England) 388 505-517
[2]  
Blennow K(2014)The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese Alzheimer’s Dement 10 439-447
[3]  
Breteler MM(2014)The prevalence of dementia in urban and rural areas of China Alzheimer’s Dement 10 1-9
[4]  
de Strooper B(2018)The cost of Alzheimer’s disease in China and re-estimation of costs worldwide Alzheimer’s Dement 14 483-491
[5]  
Frisoni GB(2011)The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics Nat Rev Drug Discov 10 698-712
[6]  
Salloway S(2016)Ultrasound treatment of neurological diseases--current and emerging applications Nat Rev Neurol 12 161-174
[7]  
Van der Flier WM(2014)A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease Ann Neurol 76 185-205
[8]  
Jia J(2016)Death associated protein kinase 1 (DAPK1): a regulator of apoptosis and autophagy Front Mol Neurosci 9 46-210
[9]  
Zhou A(2006)The death-associated protein kinases: structure, function, and beyond Annu Rev Biochem 75 189-4722
[10]  
Wei C(2017)DAPK1 signaling pathways in stroke: from mechanisms to therapies Mol Neurobiol 54 4716-47467
12345678910